Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, has announced its upcoming financial release and conference call schedule. The company will release its first quarter financial results for fiscal year 2025 on August 14, 2024. Following this, Elite's management will host a live conference call on August 15, 2024, at 11:30 AM EDT to discuss the financial and operating results, as well as provide a general business update.
Stockholders are encouraged to submit questions to the company prior to the call. The dial-in numbers for the conference are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with the conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), un'azienda farmaceutica specializzata focalizzata su prodotti generici di nicchia, ha annunciato il programma per la prossima pubblicazione dei risultati finanziari e della conferenza telefonica. L'azienda rilascerà i suoi risultati finanziari del primo trimestre per l'anno fiscale 2025 il 14 agosto 2024. Successivamente, il management di Elite ospiterà una conferenza telefonica in diretta il 15 agosto 2024 alle 11:30 AM EDT per discutere i risultati finanziari e operativi, oltre a fornire un aggiornamento generale sull'attività.
Gli azionisti sono invitati a inviare domande all'azienda prima della chiamata. I numeri per partecipare alla conferenza sono 1-800-346-7359 (nazionale) e 1-973-528-0008 (internazionale), con il numero della conferenza 98840. Una registrazione audio sarà disponibile sul sito web dell'azienda.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), una compañía farmacéutica especializada en productos genéricos de nicho, ha anunciado su próximo programa de publicación de resultados financieros y conferencia telefónica. La compañía dará a conocer sus resultados financieros del primer trimestre para el año fiscal 2025 el 14 de agosto de 2024. Posteriormente, la dirección de Elite llevará a cabo una conferencia telefónica en vivo el 15 de agosto de 2024 a las 11:30 AM EDT para discutir los resultados financieros y operativos, así como proporcionar una actualización general del negocio.
Se alienta a los accionistas a enviar preguntas a la empresa antes de la llamada. Los números para la conferencia son 1-800-346-7359 (nacional) y 1-973-528-0008 (internacional), con el número de conferencia 98840. Una grabación de audio estará disponible en el sitio web de la compañía.
엘리트 제약 주식회사(OTCQB: ELTP)는 틈새 제네릭 제품에 중점을 둔 전문 제약 회사로, 다가오는 재무 발표 및 컨퍼런스 콜 일정에 대해 발표했습니다. 이 회사는 2025 회계 연도 첫 분기 재무 결과를 2024년 8월 14일에 발표할 예정입니다. 이후 엘리트 경영진은 2024년 8월 15일 오전 11시 30분 EDT에 재무 및 운영 결과를 논의하고 일반 비즈니스 업데이트를 제공하기 위해 라이브 컨퍼런스 콜을 개최합니다.
주주들은 통화 전에 회사에 질문을 제출하도록 권장됩니다. 컨퍼런스의 다이얼인 번호는 1-800-346-7359 (국내)와 1-973-528-0008 (국제)이며, 컨퍼런스 번호는 98840입니다. 회사의 웹사이트에서 오디오 재생이 제공될 예정입니다.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), une société pharmaceutique spécialisée axée sur des produits génériques de niche, a annoncé son imminente publication financière et le calendrier de sa conférence téléphonique. La société publiera ses résultats financiers du premier trimestre de l'exercice 2025 le 14 août 2024. Par la suite, la direction d'Elite tiendra une conférence téléphonique en direct le 15 août 2024 à 11h30 EDT pour discuter des résultats financiers et opérationnels, ainsi que pour fournir une mise à jour générale sur l'activité.
Les actionnaires sont encouragés à soumettre des questions à l'entreprise avant l'appel. Les numéros d'appel pour la conférence sont 1-800-346-7359 (national) et 1-973-528-0008 (international), avec le numéro de conférence 98840. Une rediffusion audio sera disponible sur le site Web de l'entreprise.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), ein spezialisiertes Pharmaunternehmen, das sich auf Nischen-Generika konzentriert, hat seinen kommenden Finanzbericht und den Zeitplan für die Telefonkonferenz bekanntgegeben. Das Unternehmen wird seine Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 am 14. August 2024 veröffentlichen. Anschließend wird das Management von Elite am 15. August 2024 um 11:30 Uhr EDT eine Live-Konferenzschaltung abhalten, um die finanziellen und operativen Ergebnisse zu diskutieren sowie ein allgemeines Update zu den Geschäftsergebnissen zu geben.
Die Aktionäre werden ermutigt, dem Unternehmen vor der Konferenz Fragen zu stellen. Die Einwahlnummern für die Konferenz sind 1-800-346-7359 (national) und 1-973-528-0008 (international), die Konferenznummer lautet 98840. Eine Audio-Wiedergabe wird auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2025 fiscal year will be released on Wednesday, August 14, 2024. Elite's management will host a live conference call on Thursday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
Date: | August 15, 2024 |
Time: | 11:30 AM EDT |
Dial-in | 1-800-346-7359 (domestic) |
Conference number: | 98840 |
Questions: | dianne@elitepharma.com |
Audio Replay: |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219440
FAQ
When will Elite Pharmaceuticals (ELTP) release its Q1 2025 financial results?
When is Elite Pharmaceuticals (ELTP) hosting its Q1 2025 earnings call?
How can investors participate in Elite Pharmaceuticals' (ELTP) Q1 2025 earnings call?
What is the deadline for submitting questions for Elite Pharmaceuticals' (ELTP) Q1 2025 earnings call?
